NCT06145802

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors)

Single Arm Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Grit Biotechnology · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy period, a treatment and observation period, and a follow-up period.

Conditions

• Solid Tumor
• Gynecological Tumors

Interventions

Type	Name	Description
BIOLOGICAL	GT316	Autologous Tumor Infiltrating Lymphocyte Injection

Timeline

• Start date: 2023-03-09
• Primary completion: 2026-03-09
• Completion: 2026-03-09
• First posted: 2023-11-24
• Last updated: 2025-02-17

Locations

1 site across 1 country: China